	US 7,364,725 B1
	Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor
Moshe Flugelman, Haifa (Israel)
Assigned to Multi-Gene Vascular Systems Ltd., Haifa (Israel)
Filed on Jun. 04, 2002, as Appl. No. 10/163,387.
Application 10/163387 is a continuation in part of application No. 09/620227, filed on Jul. 20, 2000, abandoned.
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 63/00 (2006.01); A01N 65/00 (2006.01); A01N 43/04 (2006.01); A61K 31/00 (2006.01); C12N 15/00 (2006.01)

U.S. Cl. 424—93.1 [435/320.1; 514/44]

5 Claims

1. One or more endothelial cells genetically altered to express one or more cell adhesion factor(s), such that said genetically altered endothelial cells express said one or more cell adhesion factor(s) to an expression level that exceeds that normally produced in said endothelial cells prior to genetic alteration, wherein at least one cell adhesion factor expressed in said endothelial cells is full-length human fibulin-5 polypeptide;

and wherein said endothelial cells are genetically altered to express one or more cell proliferation growth factors, such that the genetically altered endothelial cells express said one or more cell growth factors to a expression level that exceeds that normally produced in said endothelial cells prior to genetic alteration.